Post

New research · Ophthalmology
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 12h
Cohort studyJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2026

Optic Atrophy in Wolfram Syndrome Type 1: A Retrospective Analysis of Visual Outcomes and Biomarker Correlates.

Bradley J McNeely, Abby F Tang, Fumihiko Urano … Yunshuo Tang
Read paper
OphthalmologyCohort study

Vision loss tracks with thinner retinal ganglion cell complex in Wolfram syndrome type 1.

Optic Atrophy in Wolfram Syndrome Type 1: A Retrospective Analysis of Visual Outcomes and Biomarker Correlates.

Bradley J McNeely … Yunshuo Tang
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2026
Background

Wolfram syndrome type 1 (WS1) is a rare autosomal recessive disorder classically associated with diabetes mellitus (diabetes mellitus) and optic atrophy (optic atrophy).

Purpose

We aimed to characterize optic atrophy in WS1 and evaluate optical coherence tomography (optical coherence tomography) and genetic biomarkers as tools for disease monitoring and prognostication.

Methods

We conducted a retrospective chart review of genetically confirmed patients with WS1 seen at Washington University or Indiana University neuro-ophthalmology clinics between July 2017 and 2024.

n = 31 patients
R2 = 0.29
Results
R2 = 0.29
worse vision often paired with thinner nerve cell layer, but weakly
n = 31 patients
More results

Thirty-six patients (22 women, 14 men; median age 20 years) were identified.

Median mutation severity score was 3.5.

Vision loss occurred in 31 patients; in 3 patients it was the only major symptom, in 5 patients it preceded diabetes mellitus, and in 6 patients it occurred without diabetes mellitus.

More results

Mean and median BCVA were 20/125 and 20/80, respectively.

“
Conclusion · 1 of 2

Optic atrophy was the most common and sometimes earliest WS1 manifestation. Correlations between BCVA, optical coherence tomography metrics, and mutation severity score support their potential value as biomarkers and prognostic tools.

Conclusion · 2 of 2

Findings also support considering genetic screening for WFS1 mutations in patients presenting with otherwise unexplained optic atrophy.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment